MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

Journal of Neuro-Oncology

Volumn 101, Issue 3, 2011, Pages 405-417

  Groenendijk, Floris H ^a,b   Taal, Walter ^c   Dubbink, Hendrikus J ^a   Haarloo, Cathleen R ^a   Kouwenhoven, Mathilde C ^a,c   Van Den Bent, Martin J ^c   Kros, Johan M ^a   Dinjens, Winand N M ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anaplastic astrocytoma WHO grade III; Diffuse astrocytoma WHO grade II; G:C>A:T transition mutations; MGMT promoter hypermethylation; TP53 mutation

Indexed keywords

ADENINE; CYTOSINE; GUANINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; THYMINE; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CHILD; DNA METHYLATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRESCHOOL CHILD; PRIMARY TUMOR; PROMOTER REGION; TUMOR BIOPSY; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79952195737     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0274-x     Document Type: Article

References (42)

1. Watanabe K, Sato K, Biernat W et al (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523-530 (Pubitemid 27211828)
2. Reifenberger J, Ring GU, Gies U et al (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55:822-831 (Pubitemid 26238584)
3. Peraud A, Kreth FW, Wiestler OD et al (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117-1124 (Pubitemid 34517648)
4. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453 (Pubitemid 47339290)
5. Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892-6899 (Pubitemid 39330996)
6. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489 (Pubitemid 40781150)
7. Watanabe T, Katayama Y, Yoshino A et al (2003) Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 9:4884-4890 (Pubitemid 37323294)
8. Stander M, Peraud A, Leroch B et al (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101:1028-1035
9. Okamoto Y, Di Patre PL, Burkhard C et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49-56 (Pubitemid 38961073)
10. Ichimura K, Bolin MB, Goike HM et al (2000) Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60:417-424 (Pubitemid 30070771)
11. Watanabe T, Katayama Y, Yoshino A et al (2007) Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17:5-10
12. Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 (Pubitemid 29086728)
13. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
14. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307
15. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
16. Levin N, Lavon I, Zelikovitsh B et al (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759-1765
17. Esteller M, Herman JG (2004) Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23:1-8 (Pubitemid 38142234)
18. Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857 (Pubitemid 29001538)
19. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874 (Pubitemid 38375541)
20. Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933-4938 (Pubitemid 39099766)
21. Komine C, Watanabe T, Katayama Y et al (2003) Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13:176-184 (Pubitemid 36460818)
22. Everhard S, Kaloshi G, Criniere E et al (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743 (Pubitemid 46048490)
23. Nakamura M, Watanabe T, Yonekawa Y et al (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715-1719 (Pubitemid 32952152)
24. Bello MJ, Alonso ME, Aminoso C et al (2004) Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res 554:23-32 (Pubitemid 39140812)
25. Watanabe T, Katayama Y, Komine C et al (2005) O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113:581-587 (Pubitemid 40038734)
26. Zawlik I, Vaccarella S, Kita D et al (2008) Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 32:21-29
27. Louis DNOH, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon
28. van der Sijp JR, van Meerbeeck JP, Maat AP et al (2002) Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J Clin Oncol 20:1105-1114 (Pubitemid 34141856)
29. Jeuken JW, Cornelissen SJ, Vriezen M et al (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87:1055-1065 (Pubitemid 47429190)
30. Worsham MJ, Chen KM, Meduri V et al (2006) Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:668-677 (Pubitemid 43927046)
31. Chen K, Sawhney R, Khan M et al (2007) Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 133:1131-1138 (Pubitemid 350157026)
32. Hatanpaa KJ, Burger PC, Eshleman JR et al (2003) Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 83:419-428
33. Idbaih A, Boisselier B, Marie Y et al (2007) TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet 177:103-107
34. Nakasu S, FukamiT, Jito J et al (2007) Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol 68:603-608
35. Brandes AA, Franceschi E, Tosoni a et al (2010) O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-Oncology 12:283-288
36. Ren ZP, Olofsson T, Qu M et al (2007) Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol 66:944-954
37. Park CC, Hartmann C, Folkerth R et al (2000) Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones. J Neuropathol Exp Neurol 59:1044-1050
38. Sarkar C, Ralte AM, Sharma MC, Mehta VS (2002) Recurrent astrocytic tumours - a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 16:335-342
39. Esteller M, Toyota M, Sanchez-Cespedes M et al (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368-2371
40. Whitehall VL, Walsh MD, Young J et al (2001) Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 61:827-830
41. Park TJ, Han SU, Cho YK et al (2001) Methylation of O(6)-methylguanine- DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 92:2760-2768
42. Jesien-Lewandowicz E, Jesionek-Kupnicka D, Zawlik L et al (2009) High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet Cytogenet 188:77-82